Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $1,050.00 at Wells Fargo & Company

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lowered by Wells Fargo & Company from $1,200.00 to $1,050.00 in a research report report published on Tuesday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other research reports. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating for the company in a research report on Wednesday, October 16th. TD Cowen increased their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $1,101.00.

Regeneron Pharmaceuticals Stock Down 1.3 %

REGN stock opened at $928.90 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. Regeneron Pharmaceuticals has a 1-year low of $769.19 and a 1-year high of $1,211.20. The stock has a market capitalization of $102.40 billion, a P/E ratio of 24.60, a P/E/G ratio of 3.29 and a beta of 0.12. The business has a fifty day moving average price of $1,098.29 and a 200-day moving average price of $1,040.67.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $8.79 EPS. Equities analysts forecast that Regeneron Pharmaceuticals will post 37.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in REGN. West Paces Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals during the second quarter valued at $26,000. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Finally, Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.